Followers | 10 |
Posts | 1578 |
Boards Moderated | 0 |
Alias Born | 10/15/2014 |
Monday, November 13, 2017 7:54:03 PM
Serenity was just pointing out that Zacks may be paid by Titan to cover Titan; and so if they are getting paid by Titan, there may be a bias in Titan's favor. So the comment is limited to Zacks' earning report.
I'm not too optimistic about the near-term future. Doctors are putting the ball in the insurance company's court; and the insurance companies are taking a lot of time to approve procedures. By the time the approval comes around, patients may no longer be interested.
Plus, insurance companies are not footing the whole bill for probuphine in many cases, and a lot of patients cannot afford it.
Braeburn seems to be blaming the REMS as well...requiring patients to be stablized on buprenorphine for six months, and requiring the implant to be held in a DEA approved facility, so that many doctors that want to buy it cannot keep it in their offices, thus they have to deal with the speciality pharmacy that fed ex's the implants to them on the actual day of the procedure...talk about a hassle.
Unless Braeburn lowers the price, I don't think things will get much better for probuphine anytime soon. They are being insanely greedy, and basically taking the position they would rather make no money at a high price than some money at a lower price. They also don't want to make probuphine more attractive than their injectables, because I believe them pay a higher royalty for probuphine. So they will wait to see what they can sell the injectables at, and then price probuphine just above that level. You and I know Indivior will beat them at injectables, but Derkacz got hired telling Apple Tree that he could beat Indivior. So his focus is going to be primarily there.
I was hoping for some congressional action, but that ain't gonna happen this year. Congress is focused entirely on the tax bill, so there will not be time for opioids this year. Next year though, especially before the mid-term elections, we will see some significant funding come through that hopefully will be directed to MAT, and hopefully having the DOJ going after insurance companies for failing to approve coverage. That type of thing will play well going into an election.
Derkacz is not a joke, but he inherited a mess from Sheldon, and he fired about a third of the sales reps. It will take time for that all to get sorted out.
The rest of the programs seem to be going well, we just need to find a way to pay for them! I'm hoping Titan sells 100% of its European rights to probuphine for about a year of operating expenses. Remember, the rods only cost $600, and so an EU company could sell them for $2,400 a year an still make a 100% profit.
Also, I think it makes sense for them to outlicense any but T3 if they can get cash upfront. T3 is the white whale.
Recent TTNP News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:33:11 PM
- Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria • GlobeNewswire Inc. • 01/25/2024 09:29:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:59:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 10:13:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:30:20 PM
- Titan Pharmaceuticals Announces Reverse Stock Split and Ratio • GlobeNewswire Inc. • 12/28/2023 09:15:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2023 09:47:46 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/17/2023 09:03:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 09:05:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:33:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:31:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:29:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:25:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:23:37 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 10/24/2023 09:26:34 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/23/2023 07:07:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 09:08:35 PM
- Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors • GlobeNewswire Inc. • 10/16/2023 08:37:23 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 10/04/2023 09:30:18 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 09/19/2023 08:41:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2023 08:45:22 PM
- Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock • GlobeNewswire Inc. • 09/18/2023 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 09:30:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2023 08:28:25 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM